Literature DB >> 24664509

Early Changes by (18)Fluorodeoxyglucose positron emission tomography coregistered with computed tomography predict outcome after Mycobacterium tuberculosis infection in cynomolgus macaques.

M Teresa Coleman1, Pauline Maiello, Jaime Tomko, Lonnie James Frye, Daniel Fillmore, Christopher Janssen, Edwin Klein, Philana Ling Lin.   

Abstract

Cynomolgus macaques infected with low-dose Mycobacterium tuberculosis develop both active tuberculosis and latent infection similar to those of humans, providing an opportunity to study the clinically silent early events in infection. (18)Fluorodeoxyglucose radiotracer with positron emission tomography coregistered with computed tomography (FDG PET/CT) provides a noninvasive method to measure disease progression. We sought to determine temporal patterns of granuloma evolution that distinguished active-disease and latent outcomes. Macaques (n = 10) were infected with low-dose M. tuberculosis with FDG PET/CT performed during infection. At 24 weeks postinfection, animals were classified as having active disease (n = 3) or latent infection (n = 6), with one "percolator" monkey. Imaging characteristics (e.g., lesion number, metabolic activity, size, mineralization, and distribution of lesions) were compared among active and latent groups. As early as 3 weeks postinfection, more pulmonary granulomas were observed in animals that would later develop active disease than in those that would develop latent infection. Over time, new lesions developed in active-disease animals but not in latent animals. Granulomas and mediastinal lymph nodes from active-disease but not latent animals consistently increased in metabolic activity at early time points. The presence of fewer lesions at 3 weeks and the lack of new lesion development in animals with latent infection suggest that innate and rapid adaptive responses are critical to preventing active tuberculosis. A greater emphasis on innate responses and/or rapid recruitment of adaptive responses, especially in the airway, should be emphasized in newer vaccine strategies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24664509      PMCID: PMC4019174          DOI: 10.1128/IAI.01599-13

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  19 in total

1.  Early events in Mycobacterium tuberculosis infection in cynomolgus macaques.

Authors:  Philana Ling Lin; Santosh Pawar; Amy Myers; Amarenda Pegu; Carl Fuhrman; Todd A Reinhart; Saverio V Capuano; Edwin Klein; Joanne L Flynn
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

Review 2.  Tuberculosis.

Authors:  Alimuddin Zumla; Mario Raviglione; Richard Hafner; C Fordham von Reyn
Journal:  N Engl J Med       Date:  2013-02-21       Impact factor: 91.245

3.  Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques.

Authors:  Philana Ling Lin; Veronique Dartois; Paul J Johnston; Christopher Janssen; Laura Via; Michael B Goodwin; Edwin Klein; Clifton E Barry; Joanne L Flynn
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-23       Impact factor: 11.205

Review 4.  Understanding latent tuberculosis: a moving target.

Authors:  Philana Ling Lin; Joanne L Flynn
Journal:  J Immunol       Date:  2010-07-01       Impact factor: 5.422

5.  Radiological manifestations of pulmonary tuberculosis.

Authors:  J Andreu; J Cáceres; E Pallisa; M Martinez-Rodriguez
Journal:  Eur J Radiol       Date:  2004-08       Impact factor: 3.528

6.  Tuberculosis Infection: Insight from Immunogenomics.

Authors:  Matthew Arentz; Thomas R Hawn
Journal:  Drug Discov Today Dis Mech       Date:  2007

Review 7.  Vaccine adjuvants: putting innate immunity to work.

Authors:  Robert L Coffman; Alan Sher; Robert A Seder
Journal:  Immunity       Date:  2010-10-29       Impact factor: 31.745

8.  An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis.

Authors:  Matthew P R Berry; Christine M Graham; Finlay W McNab; Zhaohui Xu; Susannah A A Bloch; Tolu Oni; Katalin A Wilkinson; Romain Banchereau; Jason Skinner; Robert J Wilkinson; Charles Quinn; Derek Blankenship; Ranju Dhawan; John J Cush; Asuncion Mejias; Octavio Ramilo; Onn M Kon; Virginia Pascual; Jacques Banchereau; Damien Chaussabel; Anne O'Garra
Journal:  Nature       Date:  2010-08-19       Impact factor: 49.962

9.  Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing.

Authors:  Philana Ling Lin; Christopher B Ford; M Teresa Coleman; Amy J Myers; Richa Gawande; Thomas Ioerger; James Sacchettini; Sarah M Fortune; JoAnne L Flynn
Journal:  Nat Med       Date:  2013-12-15       Impact factor: 53.440

Review 10.  The role of airway epithelial cells in response to mycobacteria infection.

Authors:  Yong Li; Yujiong Wang; Xiaoming Liu
Journal:  Clin Dev Immunol       Date:  2012-04-18
View more
  63 in total

Review 1.  Updates on antibody functions in Mycobacterium tuberculosis infection and their relevance for developing a vaccine against tuberculosis.

Authors:  Jacqueline M Achkar; Rafael Prados-Rosales
Journal:  Curr Opin Immunol       Date:  2018-04-12       Impact factor: 7.486

Review 2.  Heterogeneity in tuberculosis.

Authors:  Anthony M Cadena; Sarah M Fortune; JoAnne L Flynn
Journal:  Nat Rev Immunol       Date:  2017-07-24       Impact factor: 53.106

3.  Rhesus Macaques Are More Susceptible to Progressive Tuberculosis than Cynomolgus Macaques: a Quantitative Comparison.

Authors:  Philana Ling Lin; Charles A Scanga; JoAnne L Flynn; Pauline Maiello; Robert M DiFazio; Anthony M Cadena; Mark A Rodgers
Journal:  Infect Immun       Date:  2018-01-22       Impact factor: 3.441

4.  Radioiodinated DPA-713 imaging correlates with bactericidal activity of tuberculosis treatments in mice.

Authors:  Alvaro A Ordonez; Supriya Pokkali; Vincent P DeMarco; Mariah Klunk; Ronnie C Mease; Catherine A Foss; Martin G Pomper; Sanjay K Jain
Journal:  Antimicrob Agents Chemother       Date:  2014-11-17       Impact factor: 5.191

5.  A sterilizing tuberculosis treatment regimen is associated with faster clearance of bacteria in cavitary lesions in marmosets.

Authors:  Laura E Via; Kathleen England; Danielle M Weiner; Daniel Schimel; Matthew D Zimmerman; Emmanuel Dayao; Ray Y Chen; Lori E Dodd; Mike Richardson; Katherine K Robbins; Ying Cai; Dima Hammoud; Peter Herscovitch; Véronique Dartois; JoAnne L Flynn; Clifton E Barry
Journal:  Antimicrob Agents Chemother       Date:  2015-05-04       Impact factor: 5.191

6.  Positron Emission Tomography Imaging of Macaques with Tuberculosis Identifies Temporal Changes in Granuloma Glucose Metabolism and Integrin α4β1-Expressing Immune Cells.

Authors:  Joshua T Mattila; Wissam Beaino; Pauline Maiello; M Teresa Coleman; Alexander G White; Charles A Scanga; JoAnne L Flynn; Carolyn J Anderson
Journal:  J Immunol       Date:  2017-06-07       Impact factor: 5.422

7.  Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates.

Authors:  Alexander G White; Pauline Maiello; M Teresa Coleman; Jaime A Tomko; L James Frye; Charles A Scanga; Philana Ling Lin; JoAnne L Flynn
Journal:  J Vis Exp       Date:  2017-09-05       Impact factor: 1.355

8.  Early Whole Blood Transcriptional Signatures Are Associated with Severity of Lung Inflammation in Cynomolgus Macaques with Mycobacterium tuberculosis Infection.

Authors:  Hannah P Gideon; Jason A Skinner; Nicole Baldwin; JoAnne L Flynn; Philana Ling Lin
Journal:  J Immunol       Date:  2016-11-11       Impact factor: 5.422

Review 9.  Immunometabolism within the tuberculosis granuloma: amino acids, hypoxia, and cellular respiration.

Authors:  Joseph E Qualls; Peter J Murray
Journal:  Semin Immunopathol       Date:  2015-10-21       Impact factor: 9.623

10.  Imaging the evolution of reactivation pulmonary tuberculosis in mice using 18F-FDG PET.

Authors:  Allison M Murawski; Saumya Gurbani; Jamie S Harper; Mariah Klunk; Laurent Younes; Sanjay K Jain; Bruno M Jedynak
Journal:  J Nucl Med       Date:  2014-07-31       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.